Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bill.com Holdings Inc (BILL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Bill.com Holdings IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Bill.com Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Bill.com Holdings Inc trades at $49.45 (market cap $4.91B), while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 16.9× Bill.com Holdings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.

BILLREGN
Market Cap
$4.91B$83.19B
Sector
TechnologyHealth
52-Week High
$56.32$812.27
52-Week Low
$31.96$545.94
Enterprise Value
$4.62B$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bill.com Holdings Inc

BILL Holdings trades at $47.99, up 2.11% today, with a bullish technical signal from moving averages and strong institutional interest. The company reported revenue growth to $1.46B in 2025 and achieved profitability with net income of $23.80M, marking a significant turnaround from prior losses. Recent news highlights operational efficiency gains from a 30% workforce reduction and strategic focus on AI-driven financial automation for SMBs.

The outlook is positive with consistent earnings beats and analyst consensus favoring a buy rating, though high P/E of 213.91 indicates premium valuation. Key risks include intense fintech competition and reliance on SMB market stability. Upside to the $50.00 high price target depends on sustained margin expansion and successful AI integration.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bill.com Holdings Inc

Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.

Read more on BILL

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN